August 9, 2017 08:49 AM EDTUpdated 10:41 AM

Melinta will beef up its antibiotics pipeline after a merger with troubled Cempra

John Carroll

Editor & Founder

Just weeks after Melinta Therapeutics completed an R&D odyssey with an FDA approval for the antibiotic delafloxacin (Baxdela), the biotech has struck a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Melinta will beef up its antibiotics pipeline after a merger with troubled Cempra

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Melin­ta will beef up its an­tibi­otics pipeline af­ter a merg­er with trou­bled Cem­pra

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Melinta will beef up its antibiotics pipeline after a merger with troubled Cempra